Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Business Wire
Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in JanuaryAnnouncing an update to the primary efficacy endpoint data previously reported in January, which show further improvement in seizure reductions and no change in the reported safety results – bexicaserin achieved a median seizure reduction of 59.8% in countable motor seizures compared to 17.4% in the placebo group across the DEE study population. A median seizure reduction of 74.6% in Dravet Syndrome (DS), 50.8% in Lennox-Gastaut Syndrome (LGS) and 65.5% in DEE Other was achievedPACIFIC data to be presented at medical meetings in Q2 2024Preparing for End of Phase 2 Meeting with regulators and conducting start-up activities for bexicaserin’s global Phase 3 program; expect to initiate the Phase 3 program by YE 2024LP659 first-in-human Phase 1 single-ascending dose (SAD) study topline data expected Q2 2024Completed public offer
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 [Yahoo! Finance]Yahoo! Finance
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15Business Wire
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
LBPH
Earnings
- 11/2/23 - Beat
LBPH
Sec Filings
- 4/15/24 - Form 8-K
- 4/12/24 - Form ARS
- 4/12/24 - Form DEFA14A
- LBPH's page on the SEC website